Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$943.30M+500.23%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lars H. Barstad
- Sector
- Industrials
- Industry
- Marine Shipping
- Employees
- 85
- Beta
- 0.05
- Country
- CY
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.74
Financials
Revenue
$943.30M+500.2%Net Income
$659.17M+11948.5%EBITDA
$667.46M+1116.4%Free Cash Flow
$248.66MEPS (diluted)
$2.96+9766.7%Shares Outstanding (diluted)
222.62M+22.1%Operating Expenses
$12.50MCash & Debt
$322.31MReturn of Capital
$345.06MRevenue by Segment (annual)
$1.97BDividend per Share
$3.41Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.97B | $379.08M | $1.70 |
| 2024 | $2.05B | $495.58M | $2.23 |
| 2023 | $1.80B | $656.41M | $2.95 |
| 2022 | $1.43B | $475.54M | $2.22 |
| 2021 | $749.38M | $-14.96M | $-0.06 |
| 2020 | $1.22B | $412.88M | $2.11 |
| 2019 | $957.32M | $139.97M | $0.81 |
| 2018 | $742.27M | $-8.88M | $-0.05 |
| 2017 | $646.33M | $-264.86M | $-1.56 |
| 2016 | $754.31M | $117.01M | $0.75 |
| 2015 | $458.93M | $154.62M | $1.29 |
| 2014 | $241.83M | $149.47M | $1.19 |
| 2013 | $517.19M | $-188.51M | $-11.82 |
| 2012 | $578.36M | $-82.75M | $-5.31 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.50
- Implied price
- $32.53
- Return from $58.01
- -10.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $16.17 — -72.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -2.0% | -24.9% | -21.8% | -19.2% | -16.8% | -14.7% |
| 3.0% | -21.1% | -17.8% | -15.1% | -12.6% | -10.4% |
| 8.0% | -17.2% | -13.9% | -10.9% | -8.3% | -6.0% |
| 13.0% | -13.4% | -9.9% | -6.8% | -4.1% | -1.7% |
| 18.0% | -9.6% | -5.9% | -2.7% | 0.1% | 2.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-51.72%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·5d ago·Positive
Frontline Education and AI for Education Win Two Tech & Learning Best for Back to School Awards Partnership recognized in both Primary and Secondary education categories Partnership recognized in both Primary and Secondary education categories
View source ↗ - Newsglobenewswire.com·20d ago·Positive
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan 2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE)
View source ↗ - Newsglobenewswire.com·32d ago·Negative
FRO – Declares special one-time dividend after sale of two VLLCs Frontline plc (the “Company” or “Frontline”) (NYSE: FRO – OSE: FRO) refers to its announcement on August 4, 2026 regarding the sale of two VLCCs. Following the completion of the sale of the two VLCCs, the Board of Directors has declared a special one-time dividend of $0.80 per share, in line with Frontline's core strategy of returning cash to our shareholders. The special one-time dividend comes in addition to the previously declar…
View source ↗ - Newsaccessnewswire.com·41d ago·Neutral
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in eval
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Frontline plc (FRO) Q2 2026 Earnings Call Transcript Frontline plc (FRO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·47d ago·Negative
Frontline Q2 Earnings Call Highlights Frontline NYSE: FRO reported its highest quarterly profit and adjusted profit on record for the second quarter of 2026, supported by sharply higher tanker rates and market inefficiencies that management said have tightened effective vessel supply.
View source ↗
Earnings
Mon, Nov 30(in 7 weeks)
Consensus estimate $2.64 per share
Typical surprise -4.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 28$2.96 vs $2.74beat
- Fri, May 22$2.51 vs $2.44beat
- Fri, Feb 27$1.03 vs $1.15miss
- Fri, Nov 21$0.18 vs $0.27miss
- Fri, Aug 29$0.36 vs $0.42miss
- Fri, May 23$0.18 vs $0.19miss
Estimates and results for FRO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Marjorie Taylor Greenehouse · GA14 · disclosed May 7, 2025 (2d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.